BACKGROUND: Cutaneous squamous cell carcinomas (CSCC) are very common. Localized CSCC are cured by surgery and/or radiotherapy and have a better prognosis than locally inoperable advanced CSCC. Cetuximab has recently been proposed to treat locally advanced CSCC when surgery or radiotherapy cannot be offered. OBJECTIVE: The authors report results of a pilot study conducted in inoperable CSCC patients treated with cetuximab alone or combined with chemotherapy or radiotherapy. MATERIAL AND METHODS: This study was conducted in 20 CSCC patients. RECIST criteria were used to evaluate clinical and radiological responses. RESULTS: Five patients received cetuximab associated with radiotherapy (CR), nine with carboplatin (CC) and six as monotherapy (CM) over 1-month cycle treatment. Response to treatment was evaluated every two cycles. After 2 months of treatment, the authors observed nine partial responses, six stabilizations and four progressions. Disease control rate was of 78% (100% for CR, 87.5% for CC and 50% for CM) with a 47% response rate (80% for CR, 37.5% for CC and 33% for CM). CONCLUSION: The authors confirm the potential interest of cetuximab to treat unresectable advanced CSCC alone or combined with CC and CM. These results justify discussing a further randomized study combining radiotherapy and cetuximab.
BACKGROUND:Cutaneous squamous cell carcinomas (CSCC) are very common. Localized CSCC are cured by surgery and/or radiotherapy and have a better prognosis than locally inoperable advanced CSCC. Cetuximab has recently been proposed to treat locally advanced CSCC when surgery or radiotherapy cannot be offered. OBJECTIVE: The authors report results of a pilot study conducted in inoperable CSCC patients treated with cetuximab alone or combined with chemotherapy or radiotherapy. MATERIAL AND METHODS: This study was conducted in 20 CSCC patients. RECIST criteria were used to evaluate clinical and radiological responses. RESULTS: Five patients received cetuximab associated with radiotherapy (CR), nine with carboplatin (CC) and six as monotherapy (CM) over 1-month cycle treatment. Response to treatment was evaluated every two cycles. After 2 months of treatment, the authors observed nine partial responses, six stabilizations and four progressions. Disease control rate was of 78% (100% for CR, 87.5% for CC and 50% for CM) with a 47% response rate (80% for CR, 37.5% for CC and 33% for CM). CONCLUSION: The authors confirm the potential interest of cetuximab to treat unresectable advanced CSCC alone or combined with CC and CM. These results justify discussing a further randomized study combining radiotherapy and cetuximab.
Authors: Alessandro Borghi; Sergio Gianesini; Massimo Pedriali; Antonio Stefanelli; Giovanni Mangiola; Patrizia Dalla Caneva; Giovanni Lanza; Annarosa Virgili; Paolo Zamboni Journal: Int Wound J Date: 2016-01-10 Impact factor: 3.315
Authors: Giuseppina Della Vittoria Scarpati; Francesco Perri; Salvatore Pisconti; Giuseppe Costa; Filippo Ricciardiello; Salvatore Del Prete; Alberto Napolitano; Marco Carraturo; Salvatore Mazzone; Raffaele Addeo Journal: Mol Clin Oncol Date: 2016-01-27
Authors: Sara Falivene; Francesca Maria Giugliano; Antonio Maria Grimaldi; Rossella Di Franco; Diego Toledo; Matteo Muto; Fabrizio Cammarota; Valentina Borzillo; Paolo Antonio Ascierto; Paolo Muto Journal: BMC Dermatol Date: 2014-09-30